[Therapy of secondary hyperaldosteronism].
D000616:Aminoglutethimide / Q000627:therapeutic use; D002074:Butanones / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy* / Q000601:surgery; D008797:Metyrapone / Q000627:therapeutic use; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone / Q000627:therapeutic use; D014223:Triamterene / Q000627:therapeutic use; D014308:Triparanol / Q000627:therapeutic use
D002074:Butanones; D000451:Mineralocorticoid Receptor Antagonists; D000616:Aminoglutethimide; D013148:Spironolactone; D014308:Triparanol; D006493:Heparin; D014223:Triamterene; D008797:Metyrapone
La terapia dell'iperaldosteronismo secondario.